Dxd-d5

• Description :

  Dxd-d5 is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].

• Product Name Alternative :

  Exatecan-d5 derivative for ADC

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  ADC Payload; Topoisomerase

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Concentration :

  10mM

• Purity :

  98.89

• Solubility :

  DMSO : ≥ 40mg/mL

• Smiles :

  O=C1[C@](O)(C(C([2H])([2H])[2H])([2H])[2H])C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(CO)=O)C(C)=C(F)C=C6N=C4C3=C2)=O

• Molecular Formula :

  C26H19D5FN3O6

• Molecular Weight :

  498.51

• Precautions :

  H301

• References & Citations :

  [1]Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22 (20) :5097-5108.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• Isoform :

  Topo I